Gene Mutation and Clinical Characteristics of Patients with Acute Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.06.011
- Author:
Jie YANG
1
;
Yong-Bin YANG
2
;
Rui-Cang WANG
1
;
Jing-Yue LIU
1
;
Yan LI
1
;
Jun YUAN
1
;
Jie LI
3
;
Xiao-Xia ZHANG
1
;
Xiao-Han GAO
1
;
Hong-Ling HAO
1
Author Information
1. Department of Hematology,Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
2. Department of Vascular Surgery,Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
3. Department of Hematology,Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China,E-mail: doclijie@163.com.
- Publication Type:Journal Article
- Keywords:
acute leukemia;
clinical feature;
gene mutation
- MeSH:
Humans;
Retrospective Studies;
Leukemia;
Mutation
- From:
Journal of Experimental Hematology
2022;30(6):1693-1699
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the characteristics of gene mutation, clinical characteristics and significance in acute leukemia (AL) patients.
METHODS:The clinical data of 102 AL patients in Hebei General Hospital from September 2016 to September 2020 were collected and analyzed retrospectively, including the characteristics of gene mutation, age, peripheral blood cells, bone marrow blasts, leukemia subtypes and myeloperoxidase (MPO).
RESULTS:The total gene mutation rate was 87.25% (89/102) in all 102 patients. A total of 275 gene mutations were detected, with an average of 2.70 gene mutations per patient. The most frequent mutations of 102 patients were as follows: CEBPA (6.91%), NPM1 and ASXL1(6.18%), TET2 (5.82%), DNMT3A (5.45%), IDH2 and FLT3-ITD (5.09%). Gene mutations often occurred simultaneously. CEBPA mutation occurred in 10 cases of M2 subtype, while TET2 mutation occurred in 9 cases of M2 subtype. Among the most common gene mutations in MPO low expression group, mutation rates of NPM1, DNMT3A, IDH2, SF related gene mutation and RUNX1 were significantly different than those in MPO high expression group (all P<0.05). Univariate analysis showed that age, NPM1, DNMT3A and FLT3-ITD had significant effects on leukocyte level. Logistic regression analysis showed that patients with positive NPM1 mutations may had higher leukocyte levels (p=0.038), and those with positive DNMT3A mutations may had higher platelet levels (p=0.042).
CONCLUSION:The incidence of gene mutation in patients with AL is high, and it often occurs simultaneously. CEBPA and TET2 gene mutations are more common in M2 subtype. In patients with MPO low expression, the most common gene mutations are NPM1, DNMT3A and IDH2. AL patients with NPM1 gene mutation had higher white blood cell levels, while with DNMT3A gene mutation had higher platelet levels.
